ALLUVI: A IN-DEPTH INVESTIGATION INTO THE MEDICATION'S POSSIBILITIES

Alluvi, previously BI 4744, presents a notable breakthrough in weight loss therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling effectiveness in research studies, potentially surpassing existing GLP-1 site stimulators. Early findings indicate s